A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
12/2002
12/05/2002	US20020182188 Making by debulking a suspension of human liver tissue under conditions to remove mature cells, while retaining immature cells having markers for the expression of alpha-fetoprotein, and/or albumin
12/05/2002	DE10124820A1 Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut Composition and use of substances for the stabilization of sulfur-containing amino acids in blood
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448567A1 Modulators of nucleic acid ligands
12/05/2002	CA2448562A1 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448294A1 Method for treating fibrotic diseases or other indications vi
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2447657A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
12/05/2002	CA2447648A1 Pharmaceutical combinations
12/05/2002	CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/04/2002	EP1262541A1 Production of bioavailable folic acid
12/04/2002	EP1262490A1 GPib-LIPID BOND CONSTRUCT AND USE THEREOF
12/04/2002	EP1262200A2 Inhibition of platelet adherence and aggregation
12/04/2002	EP1262194A1 Remedies and preventives for antiphospholipid antibody syndrome
12/04/2002	EP1262178A2 Suppressor of anemia and appetite suppressor comprising threonine alone or in combination with methionine
12/04/2002	EP1262176A1 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261694A2 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
12/04/2002	EP1261636A2 Human protein kinases and protein kinase-like enzymes
12/04/2002	EP1261635A1 Human polynucleotides, polypeptides, and antibodies
12/04/2002	EP1261609A1 Triazolotriazinones and the use thereof
12/04/2002	EP1261606A1 Substituted oxazolidinones and their use in the field of blood coagulation
12/04/2002	EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002	EP1261583A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
12/04/2002	EP1261379A2 Genetic modification of the lung as a portal for gene delivery
12/04/2002	EP1261364A1 Method of treating or inhibiting cellular injury or cell death
12/04/2002	EP1261363A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
12/04/2002	EP1261361A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
12/04/2002	EP1261360A1 Casein derived peptides and uses thereof in therapy
12/04/2002	EP1261346A1 Modulation of cardiovascular injury
12/04/2002	EP1261336A2 Il-8 receptor antagonists
12/04/2002	EP1261329A2 Il-8 receptor antagonists
12/04/2002	EP1261328A1 Il-8 receptor antagonists
12/04/2002	EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002	EP1212352A4 Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
12/04/2002	EP1102601A4 Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells
12/04/2002	EP0971961B1 N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
12/04/2002	EP0752863B1 Use of biopolymers for digestive tract injuries treatment
12/04/2002	EP0651648B1 Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder
12/04/2002	CN1383386A Drug delivery device for insertion in vagina, rectum of nasal cavity
12/04/2002	CN1382682A 2-(alpha-hydroxypentyl) benzoate and its preparing process and usage
12/04/2002	CN1382484A Corn tassel injection and its preparing process
12/04/2002	CN1382450A Stem cell medicine for repairing damage of central nerve and its preparing process
12/04/2002	CA2384907A1 Methods and compositions relating to mek5 and cardiac hypertrophy and dilated cardiomyopathy
12/03/2002	WO2001096365A1 Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof
12/03/2002	US6489473 Pyrroloazepine derivatives
12/03/2002	US6489333 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
12/03/2002	US6489321 Nonpeptide substituted benzothiazepines as vasopressin antagonists
12/03/2002	US6489301 Solid pharmaceutical preparation for dialysis and a process for producing the same
12/03/2002	US6489298 Contulakin-G, analogs thereof and uses thereof
12/03/2002	US6489296 Treatment of hypercoagulable states or acquired protein c deficiency with activated protein c, a highly selective therapeutic agent with a low potential for causing bleeding complications
12/03/2002	US6489289 Method for establishing a dosage plan for thrombin inhibitors
12/03/2002	US6488927 Fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
12/03/2002	CA2414000A1 Pyridin-2-ylaminoalkylcarbonylglycyl-beta-alanine and derivatives
12/03/2002	CA2065644C Pyrazolopyridine compound and processes for preparation thereof
11/2002
11/28/2002	WO2002095391A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/28/2002	WO2002095067A2 INTERFERON α-14 POLYMORPHISM
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002095006A2 Muscle-specific expression vectors
11/28/2002	WO2002094997A2 Transcriptional regulation of target genes
11/28/2002	WO2002094833A1 Novel pyrrole derivatives as pharmaceutical agents
11/28/2002	WO2002094821A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	WO2002094813A1 Novel pyridyl cyanoguanidine compounds
11/28/2002	WO2002094808A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
11/28/2002	WO2002094790A1 Fused heterocyclic compound and medicinal use thereof
11/28/2002	WO2002094342A2 Compositions for protein delivery via the pulmonary route
11/28/2002	WO2002094263A2 Caspase inhibitors and uses thereof
11/28/2002	WO2002094248A2 Composition and use of substances for stabilising amino acids containing sulphur and/or for inhibiting the continuous formation of amino acids containing sulphur in a blood sample
11/28/2002	WO2002094202A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
11/28/2002	WO2002094197A2 Bicyclic inhibitors of factor xa
11/28/2002	WO2002094192A2 Antibodies against tumor necrosis factor delta (april)
11/28/2002	WO2002094186A2 Urazole compounds useful as anti-inflammatory agents
11/28/2002	WO2002094180A2 Pharmaceutically active isoindoline derivatives
11/28/2002	WO2002083712A8 Transporters and ion channels
11/28/2002	WO2002080887A3 Timed pulse release composition
11/28/2002	WO2002072631A8 Mhc molecule constructs and their usesfor diagnosis and therapy
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002047711A3 Modulators of activity of g-protein-coupled receptor kinases
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001095919A3 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
11/28/2002	WO2001092219A1 Glycinamides
11/28/2002	WO2001092214A1 Carbamic acid esters as inhibitors of factor xa
11/28/2002	WO2001089542A3 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001047468A3 Association of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020177713 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
11/28/2002	US20020177706 Rheumatic diseases; antiarthritic agents; antitumor agents
11/28/2002	US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002	US20020177609 Fatty alcohol drug conjugates

1 ... 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 ... 671